These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11472235)

  • 41. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential of ribozymes as antiviral agents.
    Sczakiel G; Nedbal W
    Trends Microbiol; 1995 Jun; 3(6):213-7. PubMed ID: 7648028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity.
    Wan MS; Fell PL; Akhtar S
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):309-17. PubMed ID: 9743468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry.
    Zhang X; Iwatani Y; Shimayama T; Yamada R; Koito A; Xu Y; Sakai H; Uchiyama T; Hattori T
    Antisense Nucleic Acid Drug Dev; 1998 Dec; 8(6):441-50. PubMed ID: 9918108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrozymes are a unique family of non-autonomous retrotransposons with hammerhead ribozymes that propagate in plants through circular RNAs.
    Cervera A; Urbina D; de la Peña M
    Genome Biol; 2016 Jun; 17(1):135. PubMed ID: 27339130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity.
    Shimayama T; Sawata S; Komiyama M; Takagi Y; Tanaka Y; Wada A; Sugimoto N; Rossi JJ; Nishikawa F; Nishikawa S
    Nucleic Acids Symp Ser; 1992; (27):17-8. PubMed ID: 1283905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ribozymes as potential anti-HIV-1 therapeutic agents.
    Sarver N; Cantin EM; Chang PS; Zaia JA; Ladne PA; Stephens DA; Rossi JJ
    Science; 1990 Mar; 247(4947):1222-5. PubMed ID: 2107573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme.
    Müller-Kuller T; Capalbo G; Klebba C; Engels JW; Klein SA
    Oligonucleotides; 2009 Sep; 19(3):265-72. PubMed ID: 19732019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1.
    Yu M; Poeschla E; Yamada O; Degrandis P; Leavitt MC; Heusch M; Yees JK; Wong-Staal F; Hampel A
    Virology; 1995 Jan; 206(1):381-6. PubMed ID: 7831794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of kinetic parameters for hammerhead and hairpin ribozymes.
    Fedor MJ
    Methods Mol Biol; 2004; 252():19-32. PubMed ID: 15017040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells.
    Yokoyama Y; Takahashi Y; Shinohara A; Lian Z; Wan X; Niwa K; Tamaya T
    Cancer Res; 1998 Dec; 58(23):5406-10. PubMed ID: 9850072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro.
    Crisell P; Thompson S; James W
    Nucleic Acids Res; 1993 Nov; 21(22):5251-5. PubMed ID: 8255782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ribozymes: structure and mechanism in RNA catalysis.
    Scott WG; Klug A
    Trends Biochem Sci; 1996 Jun; 21(6):220-4. PubMed ID: 8744356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circular RNAs with hammerhead ribozymes encoded in eukaryotic genomes: The enemy at home.
    de la Peña M; Cervera A
    RNA Biol; 2017 Aug; 14(8):985-991. PubMed ID: 28448743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted cleavage of hepatitis E virus 3' end RNA mediated by hammerhead ribozymes inhibits viral RNA replication.
    Sriram B; Thakral D; Panda SK
    Virology; 2003 Aug; 312(2):350-8. PubMed ID: 12919740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells.
    Gonzalez-Carmona MA; Schüssler S; Serwe M; Alt M; Ludwig J; Sproat BS; Steigerwald R; Hoffmann P; Quasdorff M; Schildgen O; Caselmann WH
    J Hepatol; 2006 Jun; 44(6):1017-25. PubMed ID: 16469406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.